Eribulin for heavily pre-treated metastatic breast cancer patients

• 作者: Antonia Digklia Ioannis A Voutsadakis
• 来源期刊: 世界实验医学杂志
• 学科: 医学
• 关键词: BREAST cancer METASTATIC ERIBULIN Case series RETROSPECTIVE Treatment
• 年，卷（期）: 2015,（3）
• 页码范围: 194-199
• 页数: 6页
• 分类号: R

摘要

AIM:To discuss treatment with eribulin in clinical practice outside a clinical trial.METHODS:Archives of patients treated for metastatic breast cancer were reviewed and 21 patients treated with the new chemotherapeutic eribulin mesylate,a synthetic analog of a natural marine product,were identified.Information on patients’characteristics and treatment outcomes was extracted.Treatment with eribulin mesylate was initiated at the recommended dose of 1.4 mg/m2 on days 1 and 8 of a 21-day cycle in 17 patients and at a decreased dose of 1.1 mg/m2 on days 1 and 8 of a 21-day cycle in 4 patients due to comorbidities and frailty.Efficacy of the drug was evaluated using the revised Response Evaluation Criteria in Solid Tumors criteria.Progression-Free Survival and overall survival(OS)were calculated using the Kaplan-Meier method starting from the date of eribulin therapy initiation to the date of disease progression documentation or death,respectively.RESULTS:The median age of patients at the time of eribulin mesylate treatment was 53 years(range 34-75).Sixteen patients had estrogen receptor(ER)and/or partial response(PR)positive disease and 5 had ER/PR negative disease(all triple negative).Eight patients had received 2 or 3 previous lines of chemotherapy for metastatic disease and 13 patients had received 4 or more lines of treatment.The median number of cycles of eribulin received was 3(range 1-16 years).All patients,except one,discontinued treatment due to progressive disease and one patient due to adverse effects.Six patients had a dose reduction due to side effects.All patients had progressed at the time of the report with a median time to progression of 3 mo(range 1 to 14 mo).Fifteen patients had died with a median OS of 7 mo(range 1-18 mo).Six patients were alive with a median follow-up of 13.5 mo(range 7 to 19 mo).CONCLUSION:This series of patients confirms the activity of eribulin in a heavily pre-treated metastatic breast cancer population consistent with phaseⅡandⅢtrials.